Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2021-08-17 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：第二届监事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 16th meeting of the 2nd Supervisory Board of Shanghai Medicilon Inc. It details the approval of proposals related to the 2021 restricted stock incentive plan, including the plan draft, implementation assessment methods, and verification of incentive recipients. The document includes voting results and references to further details published on the Shanghai Stock Exchange website. It is a formal announcement of board-level decisions regarding stock incentive plans, not a full report or financial statement. It does not contain financial data or detailed management discussion but rather governance and supervisory board meeting resolutions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2021-08-17 Chinese
美迪西：关于公司2021年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Shanghai Medicilon Inc. during the first half of 2021. It includes specifics on the amount raised, usage of funds, storage and management of the funds, investment projects, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and it provides financial figures and tables related to the fundraising and usage. The document length is 6594 characters, which is substantial and contains actual financial data and analysis. This matches the characteristics of a specialized report on capital raising and fund usage rather than a general annual or interim report. Therefore, the document fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-08-10 Chinese
美迪西：2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年半年度报告" which translates to "2021 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and operational details for the period January to June 2021. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes actual financial statements and substantive financial data, not just references or certifications. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2021
2021-08-10 Chinese
美迪西：2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains detailed financial data such as total assets, net profit, earnings per share, and shareholder information for the half-year period. The document explicitly states it is a summary of the half-year report and references the full half-year report for more details. The presence of comprehensive financial figures and period-specific data indicates this is a financial report for a period shorter than a full fiscal year. The document length is 3336 characters, which is consistent with a summary but still contains substantive financial data. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-10 Chinese
美迪西：独立董事关于第二届董事会第十六次会议相关事项的独立意见
Regulatory Filings
2021-08-10 Chinese
美迪西：关于召开2021年半年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2021 half-year performance explanation meeting (业绩说明会) for Shanghai Medicilon Biopharmaceutical Co., Ltd. It mentions the date, time, format (online text interaction), participants, and how investors can submit questions. It references that the 2021 half-year report and its summary have already been disclosed on the Shanghai Stock Exchange website. The document itself does not contain financial data or the report but is an announcement about the upcoming investor meeting to discuss the half-year results. The document length is short (1348 characters) and fits the pattern of a meeting announcement rather than the report or transcript itself. Therefore, it should be classified as an Investor Presentation (IP) because it is a detailed presentation for investors focusing on financials, strategy, and market position, specifically an earnings explanation meeting announcement. It is not a Call Transcript (CT) because it is not the transcript but an announcement of the meeting. It is not a Report Publication Announcement (RPA) because it does not announce the publication of the report but the meeting to discuss it. Hence, the best fit is Investor Presentation (IP).
2021-08-10 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.